Skip to Content

'
Kie K. Ang, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Gilbert H. Fletcher Distinguished Memorial Chair, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1984 Catholic University of Leuven, Leuven, Belgium, PHD, Radiation Biology
1975 Catholic University of Leuven, Leuven, Belgium, MD, Medicine

Experience/Service

Administrative Appointments/Responsibilities

Deputy Head, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1990-present

Other Appointments/Responsibilities

Chair, Board of Directors, American Society for Therapeutic Radiology and Oncology (ASTRO), Fairfax, VA, 2006-2007
President, American Society for Therapeutic Radiology and Oncology (ASTRO), Houston, TX, 1/2005-1/2006
Member, External Advisory Board, Fox Chase Cancer Center, Philadelphia, PA, 1/2001-1/2004
Chair, Head and Neck Committee, Radiation Therapy Oncology Group (RTOG), Philadelphia, PA, 1/1999-present

Endowed Positions

Gilbert H. Fletcher Memorial Chair, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1996-2000
Robert R. Herring Professorship in Clinical Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1992-1996

Selected Publications

Peer-Reviewed Original Research Articles
1. Riesterer O, Mason K, Raju U, Yang Q, Wang L, Hittelman W, Ang KK, Milas L. Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed. Radiotherapy and Oncology. In Press.
2. Eisbruch A, Harris J, Garden A, Chao C, Straube W, Harari P, Sanguineti G, Jones C, Bosch W, Ang KK. Multi-Institutional Trail of accelerated hypofractionated insensity-modulated radiation therapy for early-stage oropharngeal cancer (RTOG 00-22). Int. J. Radiation Oncology Biol. Phys. In Press.
3. Le Q, Harris J, Magliocco A, Kong C, Diaz R, Shin B, Cao H, Trotti A, Erler J, Chung C, Dicker A, Pajak T, Giaccia A, Ang KK. Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trail 90-03. Journal of Clinical Oncology. In Press.
4. Lee N, Harris J, Garden A, Straube W, Blisson B, Xia P, Bosch W, Morrison W, Quivey J, Thorstad W, Jones C, Ang KK. Intensity-Modulated Radiation Therapy with or without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. Journal of Clinical Oncology 27(22):3684-3690, 8/2009.
5. Ramdas l, Giri U, Ashorn C, Coombes K, El-Naggar A, Ang KK, Story M. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 31(5):642-654, 5/2009.
6. Moeller BJ, Rana V, Cannon BA, Williams MD, Strugis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SL, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective rishk-adjusted (18 F) Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncology 27(15):2509-15, 5/2009.
7. Lefebvre JL, Ang KK, Larynx Preservation Consensus Panel. Larynx Preservation Clinical Trial Design: Key Issues and Recommendations—A Consensus Panel Summary. Int J Radiat Oncol Biol Phys 73(5):1293-1303, 4/2009.
8. Michiels S, Le Maitre A, Buyse M, Burzhkowski T, Maillard E, Bogaerts J, Vermorken JB, Budach W, Pajak TF, Ang KK, Bourhis J, Pignon JP, on behalf of the March and MACH-NC Collaborative Groups. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 10(4):341-350, 4/2009.
9. Murphy BA, Chen A, Curran WJ Jr, Garden AS, Harari PM, Wong SJ, Ang KK. Longitudinal oncology registry of head and neck carcinoma (LORHAN (R): initial supportive care findings. Support Care Cancer, 3/2009.
10. Miller-Thomas MM, Kumar AJ, Sellin RV, Azimpoor S, Ang KK. The shrinking thyroid: how does thyroid size change following radiation therapy for laryngearl cancer? AJNR AM J Neuroradiol 30(3):316-616, 3/2009.
11. Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Kies M, Glisson B, Weber R, Garden AS. Imrt Reirradiation of Head and Neck Cancer-Disease Control and Morbidity Outcomes. Int J Clin Oncol 73(2):399-409, 2/2009.
12. Konski AA, Winter K, Cole BF, Ang KK, Fu KK. Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. Head Neck 31(2):207-212, 2/2009.
13. Meyn RE, Milas L, Ang KK. The Role of apoptosis in radiation oncology. Int J Radiat Biol 85(2):107-115, 2/2009.
14. Tripuraneni P, Watson RL, Ang KK, Harrison L, Eifel P, Zietman A, Haffty B, Thevenot LI, Willett CG, Schomberg PJ, Pickles T, Halberg FE, Devlin PM. Intersociety Radiation Oncology Summit-SCOPE II. Int J Radiat Oncol Biol Phys 72(2):323-326, 10/2008.
15. Smith GL, Smith BD, Buchholz TA, Giordano SH, Garden AS, Woodwasrd WA, Jryngikz GNm Weber RS, Ang KK, Rosenthal DI. Cerebrovascular disease risk in older head and neck cancer patients after radioitherapy. J Clin Oncol 72(2):323-326, 9/2008.
16. Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W Jr, Mehta MP. The prognostic value of nestin expresssion in newly diagnosed gliblastoma: report from the Radiatin Therapy Oncology Group. Radiat Oncol 25(3):32, 9/2008.
17. National Comprehensive Cancer Network, Forastieree AA, Ang KK, Brizel D, Brockstien BE, Burtness BA, Cmelak AJ, Colevs AD, Dunphy F, Eisele DW, Goepfert H, Hicks WL Jr, Kiess MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE< Shah JP< Spencer S, Totti A 3rd, Weber RS, Wolf GT, Worden F. Head and neck cancers. J Natl Compr Canc Netw 6(7):646-95, 8/2008.
18. Ang KK. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. Oncologist 13(8):899-910, 8/2008.
19. Rosenthal DI, Chambers MS, Fuller CD, Rebueno NC, Garcia J, Kies MS, Morrison WH, Ang KK, Garden AS. Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck Cancer. Int J Radiat Oncol Biol Phys 72(703):747-755, 2008.
20. Riesterer O, Milas L, Ang KK. Combining molecular therapeutics with radiotherapy for head and neck cancer. J Surg Oncol 97:708-11, 2008.
21. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19:142-9, 2008.
22. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582-9, 2008.
23. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, Rotman M, Meredith R, Ang KK. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 30:281-8, 2008.
24. Allen MW, Schwartz DL, Rana V, Adapala P, Morrison WH, Hanna EY, Weber RS, Garden AS, Ang KK. Long-Term Radiotherapy Outcomes for Nasal Cavity and Septal Cancers. Int J Radiat Oncol Biol Phys 71:401-6, 2008.
25. Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS, Ang KK. Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 09-14). Int J Radiat Oncol Biol Phys 71:1351-5, 2008.
26. Ramdas L, Giri U, Ashorn CL, Coombes KR, El-Naggar A, Ang KK, Story MD. miRNA expression profiles in had and neck saquamous cell carcinoma and adjacent normal tissue. Head Neck 31(5):642-54, 2008.
27. Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, Gay EG, Langer CJ. National Cancer Database report of cancer of the head and neck: 10-year update. Head Neck 31(6):748-758, 2008.
28. Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R, Treister NS, Trotti AM. NCCN Task Force Report: Prevention and Management of Mucositis in Cancer Care. J Natl Compr Canc Netw 6 Suppl 1:S1-24, 2008.
29. Thariat J, Ahamad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, Allen PK, Morrison WH, Weber RS, Ang KK. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 118:2698-709, 2008.
30. Petsuksiri J, Frank SJ, Garden AS, Ang KK, Morrison WH, Chao KS, Rosenthal DI, Schwartz DL, Ahamad A, Esmaeli B. Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 112:111-8, 2008.
31. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, Clayman GL, Garden AS, Sherman SI. Postoperative radiotherapy for advanced medullary thyroid cancer-Local disease control in the modern era. Head Neck 30(7):883-888, 2008.
32. Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, Weber RS, Lewin JS, Garden AS, Ang KK, S Wang X, Cleeland CS. The development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 2007(29):923-31, 2008.
33. Rosenthal DI, Mendoza TR, Chambers MS, Burkett VS, Garden AS, Hessell AC, Lewin JS, Ang KK, Kies MS, Gning I, Wang XS, Cleeland CS. The M.D. Anderson Sympton Inventory-Head and Neck Module, A Patient-Reported Outcome Instrument, Accurately Predicts The Severity of Radiation-Induced Mucositis. Int J Radiat Oncol Biol Phys 72(5):1355-1361, 2008.
34. Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly M S. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 67:870-8, 3/2007. PMID: 17293237.
35. Ryu JK, Swann S, Leveque F, Scarantino CW, Johnson D, Chen A, Fortin A, Pollock J, Kim H, Ang KK. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: A double-blind placebo-controlled prospective Phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys 67:643-50, 3/2007. PMID: 17293228.
36. Garden AS, Morrison WH, Wong PF, Tung SS, Rosenthal DI, Dong L, Mason B, Perkins GH, Ang KK. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 67:438-44, 2/2007. PMID: 17141972.
37. Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M, Ang KK. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67:568-72, 2/2007. PMID: 17236972.
38. Cooper JS, Mukherji SK, Toledano AY, Beldon C, Schmalfuss IM, Amdur R, Sailer S, Loevner LA, Kousouboris P, Ang KK, Cormack J, Sicks J. An evaluation of the variability of tumor-shape definition derived by experienced observers from CT images of supraglottic carcinomas (ACRIN protocol 6658). Int J Radiat Oncol Biol Phys 67:972-75, 1/2007. PMID: 17208386.
39. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Annual Oncology 19:142-9, 2007.
40. Thariat J, Milas L, Ang KK. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69:974-84, 2007.
41. Calvin DP, Hammond ME, Pajak TF, Trotti AM, Meredith RF, Rotman M, Jones CU, Byhardt RW, Demas WF, Ang KK, Fu KK; Radiation Therapy Oncology Group 90-03 Trial. Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol 30:406-19, 2007.
42. Petsuksiri J, Frank SJ, Garden AS, Ang KK, Morrison WH, Chao KS, Rosenthal DI, Schwartz DL, Ahamad A, Esmaeli B. Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 112:111-8, 2007.
43. O'Daniel JC, Garden AS, Schwartz DL, Wang H, Ang KK, Ahamad A, Rosenthal DI, Morrison WH, Asper JA, Zhang L, Tung SM, Mohan R, Dong L. Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get? Int J Radiat Oncol Biol Phys 69:1290-6, 2007.
44. Bristol IJ, Ahamad A, Garden AS, Morrison WH, Hanna EY, Papadimitrakopoulou VA, Rosenthal DI, Ang KK. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys 68:719-30, 2007.
45. Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191-7, 2007.
46. Chung CH, Wong S, Ang KK, Hammond EH, Dicker AP, Harari PM, Le QT. Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program. Int J Radiat Oncol Biol Phys 63:S67-8, 2007.
47. Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarizing adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8:613-24, 2007.
48. Harari PM, Cohen RB, Raben D, Myers JN, Vokes EE, Weber RS, Ang KK. The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. Int J Radiat Oncol Biol Phys 69:S1-3, 2007.
49. O’Daniel JC, Rosenthal DI, Garden AS, Barker JL, Ahamad A, Ang KK, Asper JA, Blanco AI, de Crevoisier R, Holsinger FC, Patel CB, Schwartz DL, Wang H, Dong L. The effect of dental artifacts, contrast media, and experience on interobserver contouring variations in head and neck anatomy. Am J Clin Oncol 30:191-8, 2007.
50. Hopewell JW, Millar WT, Ang KK. Toward improving the therapeutic ration in stereotactic radiosurgery: selective modulation of the radiation responses of both normal tissues and tumor. J Neurosurg 107:84-93, 2007.
51. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maitre A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843-54, 9/2006. PMID: 16950362.
52. Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre JL, Leupold N, List MA, O'Malley BO, Patel S, Posner MR, Schwartz MA, Wolf GT. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24:3693-704, 8/2006. PMID: 16832122.
53. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ, Yarbrough WG. Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-{kappa}B Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma. Cancer Res 66:8210-8, 8/2006. PMID: 16912200.
54. Giri U, Ashorn CL, Ramdas L, Stivers DN, Coombes K, El-Naggar AK, Ang KK, Story MD. Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation. Int J Radiat Oncol Biol Phys 64(3):670-7, 3/2006. PMID: 16289374.
55. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567-78, 2/2006. PMID: 16467544.
56. Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 23(13):3008-15, 5/2005. PMID: 15860857.
57. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:843-850, 2005.
58. Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas L. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59(4):1163-73, 7/2004. PMID: 15234052.
59. Gregoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C, Hamoir M, Lee N, Maingon P, Muller K, Reychler H. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol 69(3):227-36, 12/2003. PMID: 14644481.
60. Barker JL, Jr, Glisson BS, Garden AS, El-Naggar AK, Morrison WH, Ang KK, Chao KS, Clayman G, Rosenthal DI. Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer 98(11):2322-8, 12/2003. PMID: 14635065.
61. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57(1):246-54, 9/2003. PMID: 12909240.
62. Ballo MT, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am 83(2):323-42, 4/2003. PMID: 12744612.
63. Ballo, MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, Schechter NR, Morrison WH, Ross MI, Ang KK. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97(7):1789-96, 2003.
64. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350-6, 12/2002. PMID: 12499279.
65. Nguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol 3(11):693-701, 11/2002. PMID: 12424072.
66. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, Geara FB, Klotch DW, Goepfert H, Peters LJ. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 51(3):571-8, 11/2001. PMID: 11597795.
67. Ang KK, Jiang GL, Feng Y, Stephens LC, Tucker SL, Price RE. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 50(4):1013-20, 7/2001. PMID: 11429229.
68. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48(1):7-16, 8/2000. PMID: 10924966.
69. Milas, L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang KK, Mendelsohn J, Fan Z. In Vivo Enhancement of Tumor Radioresponse by C225 Anti-epidermal Growth Factor Receptor Antibody. Clinical Cancer Research 6:701-8, 2000.

Invited Articles
1. Meyn RE, Milas L, Ang KK. The role of apoptosis in radiation oncology. Int J Radiat Biol 85(2):107-15, 2009.
2. Thariat J, Yildirim G, Mason KA, Garden AS, Milas L, Ang KK. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol 12:99-110, 2007.

Abstracts
1. Raju U, Riesterer R, Molkentine D, Pickett J, Milas L, Ang KK. Dasatinib (BMS-354825) an inhibitor of src kinases, enhanced human cancer cell raiosensivity and suppressed cell invasion, migration and metastasis. ICTR March 2009, 2009.
2. Curran W, Chen A, Garden S, Harari P, Murphy A, Wong S, Bellm L, Schwartz M, Dawson D, Ang K. Longitudinal oncology registry of head and neck carcinoma (LORHAN): First report of outcomes. J Clin Oncol 27(15S), 2009.
3. Gillison M, Harris J, Westra W, Chung C, Jordan R, Rosenthal D, Nguyen-Tan P, Spanos D, Redmond , Ang KK. Survival outcomes by tumor human papillomavius (HPV) status in stage III-IV oropharyngeal cancer (OPC) in Trog 0129. J Clin Oncol (ASCO 2009 Annual Meeting) 27(15s), 2009.
4. Torres M, Raju U, Milas L, Ang KK. A pan Her inhibitor, BMS-599626, augments radiosensitivity of head and neck squamous carcinoma cells (HNSCC) in vitro and increases HNSCC tumor radioresponse in vivo. AACR Meeting April 2008, 2008.
5. Raju U, Riesterer O, Molkentine D, Milas L, Ang KK, University of Texas MD Anderson Cancer Center. Identification of kinases that are potential molecular determinants of cellular response to radiation using antibody arrays. 20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva, Switzerland, 21-24 October 2008, 2008.
6. Raju U, Johnson F, Glisson B, Riesterer O, Milas L, Ang KK, University of Texas M.D. Anderson Cancer Center. Mechanisms of enhanced radiosensitivity of human head and neck squamous cell carcinomas by dasatinib (BMS-354825, an inhibitor of Src kinases) include induction of apoptosis and inhibition of DNA reapair. AACR Meeting 2008, 2008.
7. Valdecenas D, Milas L, Mason K, Carpenter J, Freeman D, Polverino A, Ang KK. Panitumumab (pmab), a fully human anti-epidermal growth factor (EGFr) inhibitor, and motesanib diphosphate, an oral inhibitor of angiogenesis with direct antitumor activity, enhance tumor radioresponse. Radiation Research Society Meeting, Boston, MA 2008, 2008.
8. Riesterer O, Pickett J, Patel N, Raju U, Hicklin D, Ang KK, Milas L, UT MD Anderson cancer Center, IMClone systems. Tumor bed irradiation enhances sensitivity of A431 tumor exenografts to C225 anti-EGFR antibody. AACR Meting Abstracts, 2008.
9. Torres M, Raju U, Milas L, Ang KK. A pan Her inhibitor, BMS-599626, augments radiosensitivity of HN5 cells by increasing radiation-induced apoptosis and inhibiting DNA repair. AACR Meeting October 2007, 2007.
10. Ang KK, Pajak T, Rosenthal DI, Nguyen F, Lu C, Kim H, Axelrod R, List M, Silverman C, Weber RS. A phase III trial to compare standard versus accelerated fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): Report of compliance and toxicity. Proceedings of the ASTRO Annual Meeting 69:S12, 2007.
11. Michiels S, LeMaitre A, Buyse M, Burzykowski T, Bogaerts J, Vermorken JB, Budach W, Ang KK, Pajak T, Pignon JP. Surrogate endpoints for overall survival (OS) in head and neck squamous cell carcinoma (HNSCC): Evaluation using individual data of 23,737 patients. Proceedings of the 2007 ASCO Annual Meeting:307s, 2007.

Book Chapters
1. Ahamad A, Ang KK. Nasal Cavity and Paranasal Sinuses. In: Principles and Practice of Radiation Oncology, 5th. Ed(s) Halperin EC, Perez CA, Brady LW. Lippincott Williams & Wilkins: Philadelphia, 858-73, 2008.
2. Ang KK, Weber RS. Cutaneous Carcinoma. In: Clinical Radiation Oncology, 2nd. Ed(s) Gunderson LL, Tepper JE. Churchill Livingston: Philadelphia, 853-64, 2007.
3. Garden AS, Morrison WH, Ang KK. Larynx and Hypopharynx Cancer. In: Clinical Radiation Oncology, 2nd. Ed(s) Gunderson LL, Tepper JE. Churchill Livingston: Philadelphia, 727-54, 2007.
4. Ballo MT, Ang KK. Malignant Melanoma. In: Clinical Radiation Oncology, 2nd. Ed(s) Gunderson LL, Tepper JE. Churchill Livingston: Philadelphia, 865-78, 2007.
5. Morrison WH, Garden AS, Ang KK. Oropharyngeal Cancer. In: Clinical Radiation Oncology, 2nd. Ed(s) Gunderson JL, Tepper JE. Churchill Livingston: Philadelphia, 673-704, 2007.
6. Ang KK. Part B: Head and Neck, Overview. In: Clinical Radiation Oncology, 2nd. Ed(s) Gunderson LL, Tepper JE. Churchill Livingston: Philadelphia, 629-37, 2007.
7. Ahamad A, Bristol IJ, Garden AS, Ang KK. Sinonasal Cancer. In: Clinical Radiation Oncology, 2nd. Ed(s) Gunderson LL, Tepper JE. Churchill Livingston: Philadelphia, 755-80, 2007.

Letters to the Editor
1. Bonner JA, Ang KK. More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 5:514-5, 2007.

Last updated: 8/26/2009